Keryx Biopharmaceuticals Stockholders Approve Merger with Akebia Therapeutics
11 déc. 2018 12h00 HE
|
Keryx Biopharmaceuticals, Inc.
BOSTON, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today...
Glass Lewis Recommends that Keryx Biopharmaceuticals Stockholders Vote “FOR” the Proposed Merger with Akebia Therapeutics
30 nov. 2018 08h55 HE
|
Keryx Biopharmaceuticals, Inc.
BOSTON, Nov. 30, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today...
ISS Recommends that Keryx Biopharmaceuticals Stockholders Vote “FOR” the Proposed Merger with Akebia Therapeutics
29 nov. 2018 07h00 HE
|
Keryx Biopharmaceuticals, Inc.
BOSTON, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today...
Keryx Biopharmaceuticals Announces Third Quarter 2018 Financial Results
08 nov. 2018 16h30 HE
|
Keryx Biopharmaceuticals, Inc.
Third quarter 2018 total revenues of $28.0 million including net U.S. Auryxia® (ferric citrate) product sales of $26.6 million, a 96 percent increase compared to the third quarter of 2017Approximately...
Keryx Biopharmaceuticals to Release Third Quarter 2018 Financial Results on Thursday, November 8, 2018
06 nov. 2018 16h30 HE
|
Keryx Biopharmaceuticals, Inc.
BOSTON, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today...
Keryx Biopharmaceuticals Announces Filing of Definitive Joint Proxy Statement in Connection with Pending Merger with Akebia Therapeutics
30 oct. 2018 17h31 HE
|
Keryx Biopharmaceuticals, Inc.
Keryx Board Unanimously Supports Merger with Akebia and Encourages Stockholders to vote “FOR” the Merger Proposals Keryx Special Meeting of Stockholders Scheduled for December 11, 2018 BOSTON, Oct. ...
Keryx Biopharmaceuticals Announces Participation in an Upcoming Investor Conference
01 oct. 2018 09h16 HE
|
Keryx Biopharmaceuticals, Inc.
BOSTON, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today...
Keryx Biopharmaceuticals Announces Second Quarter 2018 Financial Results
08 août 2018 07h00 HE
|
Keryx Biopharmaceuticals, Inc.
Second quarter 2018 total revenues of $25.7 million, including net U.S. Auryxia® (ferric citrate) product sales of $24.1 million; a 71 percent increase compared to the second quarter of...
Keryx Biopharmaceuticals to Host Conference Call of Second Quarter 2018 Financial Results on Wednesday, August 8, 2018
02 août 2018 16h05 HE
|
Keryx Biopharmaceuticals, Inc.
BOSTON, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today...
Keryx Biopharmaceuticals Announces Participation in a Renal Disease Panel at the JMP Securities Life Sciences Conference on Thursday, June 21st
20 juin 2018 09h21 HE
|
Keryx Biopharmaceuticals, Inc.
BOSTON, June 20, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today...